In both outpatient and hospital settings, empiric therapy is recommended for all persons 65 and older with suspected or confirmed influenza, even if disease is not currently severe. Providers should encourage their patients to seek treatment immediately after illness onset, and should prescribe antiviral medication as appropriate. There are three FDA-approved influenza antiviral drugs recommended by CDC this season. The brand names for these are Tamiflu® (generic name oseltamivir), Relenza® (generic name zanamivir), and Rapivab® (generic name peramivir). Peramivir was approved in December 2014. It is given intravenously (by IV).